文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

NLRC5 可能通过诱导 PD-L1 表达促进子宫内膜癌进展。

NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.

机构信息

533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

36639The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

出版信息

Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221112742. doi: 10.1177/15330338221112742.


DOI:10.1177/15330338221112742
PMID:35880269
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9340384/
Abstract

The NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5 (NLRC5) was dysregulated in endometrial cancer (EC). However, the potential regulatory mechanisms of NLRC5 in EC remained unclear. We aimed to explore whether NLRC5 could regulate the programmed cell death protein ligand 1 (PD-L1) in EC. We also investigated the related molecular which led to the inactivation of NLRC5 in EC. The expressions of NLRC5 and PD-L1 in endometrium tissue microarray were detected by immunohistochemistry. Pearson's correlation analysis was performed to detect the expression correlation between NLRC5 and PD-L1. Immunofluorescence staining, western blotting, and quantitative real-time PCR (qRT-PCR) were used to detect the role of NLRC5 in PD-L1 in EC cell lines. The somatic mutation in EC patients was detected by whole-exome sequencing (WGS). NLRC5 was downregulated in the endometrium of EC patients when compared to those in the normal endometrium. The level of PD-L1 in the endometrium of EC patients was higher when compared to those in the normal endometrium. There was a negative expression correlation between NLRC5 and PD-L1. NLRC5 could promote the expression of PD-L1 in EC cell lines. The mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. NLRC5 could inhibit the activation of PD-L1 in EC. Mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. Future study should investigate the mechanism of NLRC5 in PD-L1, as well as the mechanism of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK in NLRC5.

摘要

核苷酸结合寡聚化结构域样受体(NLR)家族、包含半胱天冬酶募集结构域(CARD)的 5 型(NLRC5)在子宫内膜癌(EC)中失调。然而,NLRC5 在 EC 中的潜在调节机制仍不清楚。我们旨在探讨 NLRC5 是否可以调节 EC 中的程序性细胞死亡蛋白配体 1(PD-L1)。我们还研究了导致 EC 中 NLRC5 失活的相关分子。通过免疫组织化学检测子宫内膜组织微阵列中 NLRC5 和 PD-L1 的表达。采用 Pearson 相关性分析检测 NLRC5 与 PD-L1 表达的相关性。免疫荧光染色、Western blot 和实时定量 PCR(qRT-PCR)用于检测 NLRC5 在 EC 细胞系中对 PD-L1 的作用。通过全外显子组测序(WGS)检测 EC 患者的体细胞突变。与正常子宫内膜相比,EC 患者的子宫内膜中 NLRC5 下调。与正常子宫内膜相比,EC 患者的子宫内膜中 PD-L1 水平较高。NLRC5 与 PD-L1 呈负表达相关性。NLRC5 可促进 EC 细胞系中 PD-L1 的表达。ANKRD20A2、C2orf42、ADGRB3、AVPR2、GOLGA6C 和 IPPK 的突变可能导致 EC 患者 NLRC5 的下调。NLRC5 可抑制 EC 中 PD-L1 的激活。ANKRD20A2、C2orf42、ADGRB3、AVPR2、GOLGA6C 和 IPPK 的突变可能导致 EC 患者 NLRC5 的下调。未来的研究应探讨 NLRC5 在 PD-L1 中的作用机制,以及 ANKRD20A2、C2orf42、ADGRB3、AVPR2、GOLGA6C 和 IPPK 在 NLRC5 中的作用机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/eea426e045e0/10.1177_15330338221112742-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/d0e34f35cd8d/10.1177_15330338221112742-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/4cbc13794468/10.1177_15330338221112742-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/e3c20721bbdb/10.1177_15330338221112742-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/eea426e045e0/10.1177_15330338221112742-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/d0e34f35cd8d/10.1177_15330338221112742-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/4cbc13794468/10.1177_15330338221112742-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/e3c20721bbdb/10.1177_15330338221112742-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d6/9340384/eea426e045e0/10.1177_15330338221112742-fig4.jpg

相似文献

[1]
NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.

Technol Cancer Res Treat. 2022

[2]
BMI1 induces ubiquitination and protein degradation of Nod-like receptor family CARD domain containing 5 and suppresses human leukocyte antigen class I expression to induce immune escape in non-small cell lung cancer.

Kaohsiung J Med Sci. 2022-12

[3]
LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.

Cancer Lett. 2022-3-31

[4]
NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.

J Int Med Res. 2020-5

[5]
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency.

Sci Rep. 2024-5-30

[6]
MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.

Pathol Res Pract. 2019-7-22

[7]
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.

PLoS One. 2018-2-6

[8]
Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.

Autophagy. 2022-4

[9]
NLRC5 exerts anti-endometriosis effects through inhibiting ERβ-mediated inflammatory response.

BMC Med. 2024-9-2

[10]
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.

Am J Surg Pathol. 2020-2

引用本文的文献

[1]
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency.

Sci Rep. 2024-5-30

本文引用的文献

[1]
Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.

Anticancer Res. 2022-3

[2]
Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.

Cell Oncol (Dordr). 2021-6

[3]
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.

Vaccines (Basel). 2020-11-24

[4]
Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.

Eur J Cancer. 2021-1

[5]
Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression.

Oncogene. 2021-1

[6]
PD-L1 degradation pathway and immunotherapy for cancer.

Cell Death Dis. 2020-11-6

[7]
NLRC5 Inhibits Inflammation of Secretory Phase Ectopic Endometrial Stromal Cells by Up-Regulating Autophagy in Ovarian Endometriosis.

Front Pharmacol. 2020-8-18

[8]
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.

Cancer Immunol Res. 2020-10

[9]
PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.

Cell Death Dis. 2020-7-6

[10]
NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.

J Int Med Res. 2020-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索